Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.52 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.45 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 4/20 | 0.45 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL957978 | 0.87 | SLC22A12 (0.68) | SLC22A12LTB4RLTB4R2MAOBFFAR1 | |
| SCHEMBL1010327 | 0.83 | SLC22A12 (0.50) | SLC22A12LTB4RLTB4R2MAOBF10 | |
| SCHEMBL1718777 | 0.83 | SLC22A12 (0.50) | SLC22A12LTB4RLTB4R2 | |
| SCHEMBL2848980 | 0.82 | NR4A2 (0.62) | LTB4RLTB4R2MAOBSPHK2SPHK1 | |
| SCHEMBL4010528 | 0.80 | TP53 (0.51) | LTB4RLTB4R2NR1H3 | |
| SCHEMBL1718631 | 0.79 | SPHK2 (0.49) | SLC22A12SPHK2SPHK1 | |
| SCHEMBL956735 | 0.79 | FFAR1 (0.62) | SLC22A12FFAR1 | |
| SCHEMBL955739 | 0.79 | SLC22A12 (0.57) | SLC22A12LTB4RLTB4R2FFAR1 | |
| SCHEMBL6754441 | 0.79 | NR1H3 (0.53) | PLA2G2ANR1H3 | |
| SCHEMBL15297886 | 0.79 | SLC22A12 (0.57) | SLC22A12MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1868595-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2012-01-11 | — | — | EP | claimed |
| US-8022249-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-09-20 | — | — | US | claimed |
| US-20090234016-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-09-17 | — | — | US | claimed |
| EP-1868595-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2006127133-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2006-11-30 | — | — | WO | claimed |
| EP-1868595-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-1868595-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2012-01-11 | — | — | EP | disclosed |
| US-8022249-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022249-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090234016-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090234016-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |
| EP-1868595-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006127133-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234016-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | CPT1B, CPT1A, GPR119 | SLC22A12 2014/4885LTB4R 2098/4885LTB4R2 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.